Cited by 340Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Open access

Desai, Brinda S., Monahan, Angela J., Carvey, Paul M., Hendey, Bill·2007·Cell Transplantation

DOI 10.3727/000000007783464731

Open this paper in CoChat — free account

Abstract

The blood–brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.

Integrity signals

Registry

Crossref · 10.3727/000000007783464731

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
J. Submicrosc. Cytol. Pathol.
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287

Show all 117 references

Research works printed but not linked: 14

Bernheimer H., 1973, Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415
Dahlstrom A., 1990, J. Neural Transm. Suppl., 29, 195
Desai B. S., 2006, Soc. Neurosci. Abstr.
Ehrlich P., 1904, Gesammelte Arbeiten zur Immunitaetsforschung, 574
Goldmann E., 1913, Abhandl Konigl preuss Akad Wiss, 1, 1
Iwasaki T., 1999, J. Med. Dent. Sci., 46, 31
Kalaria R. N., 1992, Cerebrovasc. Brain Metab. Rev., 4, 226
Kemper E. M., 2004, Rev., 30, 415
Larsen N., 2005, Soc. Neurosci. Abstr.
Parachikova A., 2006, Neurobiol. Aging
Sayre L. M., 2000, Cell. Mol. Biol. (Noisy-le-grand), 46, 731
Simpson I. A., 2002, Diabetes Nutr. Metab., 15, 281
Verbeek M. M., 1994, Am. J. Pathol., 144, 104
Zipser B. D., 2006, Neurobiol. Aging;

Sorted by citations

Items 201–300 of 340

Low-Intensity Pulsed Ultrasound Enhanced Neurite Guidance Growth through Netrin-1/DCC Signal Pathway in Primary Cultured Cortical Neurons of Rats
Wen, J., Deng, X., Huang, C., An, Z., & Liu, M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00020 · Cited by 15
Synthesis of polymeric nanocapsules by radical UV-activated interface-emulsion polymerization
Bazzano, M., Pisano, R., Brelstaff, J., Spillantini, M. G., Sidoryk‐Wȩgrzynowicz, M., Rizza, G., & Sangermano, M. (2016) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.28226 · Cited by 14
Treatment and protective effects of metalloproteinase inhibitors alone and in combination with N-Acetyl cysteine plus vitamin E in rats exposed to aflatoxin B1
Traş, B., Faki, H. E., Kutahya, Z. O., Bahçıvan, E., Dik, B., Bozkurt, B., & Üney, K. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.02.012 · Cited by 14
Postulated vasoactive neuropeptide immunopathology affecting the blood–brain/blood–spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
Marshall‐Gradisnik, S. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4176 · Cited by 14
Interplay between Systemic Glycemia and Neuroprotective Activity of Resveratrol in Modulating Astrocyte SIRT1 Response to Neuroinflammation
Grabowska, A. D., Wątroba, M., Witkowska, J., Mikulska, A., Sepúlveda, N., & Szukiewicz, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411640 · Cited by 13
A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson’s disease
Schneider, J. S. (2021) · Glycoconjugate Journal · doi:10.1007/s10719-021-10002-2 · Cited by 13
New Targets for Parkinson's Disease: Adhesion G Protein-Coupled Receptor B1 is Downregulated by AMP-Activated Protein Kinase Activation
Choi, J., Bae, W., Nam, S., & Jeong, J. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0047 · Cited by 13
GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms
Schneider, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119183 · Cited by 13
The Common Denominators of Parkinson’s Disease Pathogenesis and Methamphetamine Abuse
Vincent, B., & Shukla, M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230907151226 · Cited by 13
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments
Guglielmi, G., Zamagni, C., Re, M. D., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177076 · Cited by 13
Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells?
Prytkova, I., Goate, A., Hart, R. P., & Slesinger, P. A. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13811 · Cited by 12
Degenerative disease‐on‐a‐chip: Developing microfluidic models for rapid availability of newer therapies
Jahagirdar, D., Bangde, P. S., Jain, R. D., & Dandekar, P. P. (2021) · Biotechnology Journal · doi:10.1002/biot.202100154 · Cited by 13
Blood-brain barrier permeability differentiates Sadowski mouse lines of high and low stress-induced analgesia: electron microscopy analysis.
Gajkowska, B., Kosson, A., Sacharczuk, M., Kossoń, P., & Lipkowski, A. W. (2011) · PubMed · Cited by 12
Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axis
Johnson, A. M., Ou, Z.-Y. A., Gordon, R., & Saminathan, H. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106113 · Cited by 11
Differentiation of Human Induced Pluripotent Stem Cells to Brain Microvascular Endothelial Cell-Like Cells with a Mature Immune Phenotype
Matsuo, K., Engelhardt, B., & Nishihara, H. (2023) · Journal of Visualized Experiments · doi:10.3791/65134 · Cited by 11
Anti-Chol-1 Antigen, GQ1bα, Antibodies Are Associated with Alzheimer’s Disease
Ariga, T., Kubota, M., Nakane, M., Oguro, K., Yu, R. K., & Ando, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063326 · Cited by 11
Cerebral and cerebellar histological changes in the rat animal model of rotenone induced parkinsonism can be ameliorated by bone marrow derived stem cell conditioned media
Abdelwahab, S. A., Elsebay, S. A. G., Ibrahim, M. F. G., & Hafez, S. M. N. A. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101892 · Cited by 11
Proteins and transcriptional dysregulation of the brain extracellular matrix in Parkinson’s disease: A systematic reviewPreprint
Rike, W. A., & Stern, S. (2023) · medRxiv · doi:10.1101/2023.03.01.23286630 · Cited by 11
Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy
for the Altair Study Group, Winston, A., Duncombe, C. J., Li, P. C., Gill, M. J., Kerr, S. J., Puls, R. L., Taylor-Robinson, S. D., Emery, S., & Cooper, D. A. (2012) · Neuroradiology · doi:10.1007/s00234-012-1061-5 · Cited by 10
Do Periodontal Pathogens or Associated Virulence Factors Have a Deleterious Effect on the Blood-Brain Barrier, Contributing to Alzheimer’s Disease?
Kouki, M. A., Pritchard, A. B., Alder, J. E., & Crean, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215103 · Cited by 14
Beta-caryophyllene inhibits the permeability of the blood–brain barrier in MPTP-induced parkinsonism
Ramos-Molina, A. R., Tejeda-Martínez, A. R., Paredes, J. M. V., Chaparro-Huerta, V., Urmeneta-Ortíz, M. F., Ramírez-Jirano, L. J., & Flores-Soto, M. E. (2023) · Neurología · doi:10.1016/j.nrl.2022.11.004 · Cited by 11
Changes in the blood–brain barrier status closely correlate with the rate of disease progression in patients with multiple system atrophy: A longitudinal study
Lee, J. E., Song, S., Hong, J. Y., Sunwoo, M.-K., Park, H.-J., Sohn, Y. H., & Lee, P. H. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.12.002 · Cited by 10
Clonal haematopoiesis of emerging significance
Hammond, D. E., & Loghavi, S. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.005 · Cited by 10
Biomarkers of HIV-1-Associated Neurocognitive Disorders: Challenges of Proteomic Approaches
Ciborowski, P. S. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.63 · Cited by 10
Oxidants and Endothelial Dysfunction
Lund, A. K. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00712-0 · Cited by 12
Identification of mitochondrial-related genes as potential biomarkers for the subtyping and prediction of Alzheimer’s disease
Ma, W., Su, Y., Zhang, P., Wan, G., Cheng, X., Lu, C., & Gu, X. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1205541 · Cited by 9
Improvement of the hydrophilicity of 7, 8-dihydroxyflavone by in situ grafting of PEG-A via RAFT polymerization and the drug efficacy tests
Chen, T., Han, X., Peng, Z. W., Li, A., & Liu, J. (2016) · European Polymer Journal · doi:10.1016/j.eurpolymj.2016.06.019 · Cited by 9
Heterochromatic silencing of immune‐related genes in glia is required for BBB integrity and normal lifespan in drosophila
Shu, S., Jiang, M., Deng, X., Yue, W., Cao, X., Zhang, K., Wang, Z., He, H., Cui, J., Wang, Q., et al. (2023) · Aging Cell · doi:10.1111/acel.13947 · Cited by 9
Protein aggregation-inhibition: a therapeutic route from Parkinson’s disease to sickle cell anemia
Martins, G. F., & Galamba, N. (2023) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2023.2201406 · Cited by 9
Cell Culture Models for Drug Transport Studies
Kalashnikova, I. V., Albekairi, N. A., Ali, S., Al-Enazy, S., & Rytting, E. (2016) · Drug Delivery · doi:10.1002/9781118833322.ch7 · Cited by 9
Microfluidic and Computational Tools for Neurodegeneration Studies
Gomez, K., Yarmey, V. R., Mane, H., & San‐Miguel, A. (2025) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-082223-054547 · Cited by 8
Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs)
Zeitouni, S., Ford, B. S., Harris, S. M., Whitney, M. J., Gregory, C. A., & Prockop, D. J. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-75 · Cited by 8
Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders
Kim, H., Wu, K. L., Tam, K.-W., Chan, Y., & Shum, D. K. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.12.007 · Cited by 7
Thyroid Hormone and Alzheimer Disease: Bridging Epidemiology to Mechanism
Escamilla, S., & Salas-Lucia, F. (2024) · Endocrinology · doi:10.1210/endocr/bqae124 · Cited by 9
The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes
Chen, J., Dong, X., Lin, Y., & Lv, C. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155985 · Cited by 7
Immunological aspects of Parkinson's disease
Belova, O. V., Arefieva, T. I., & Moskvina, S. N. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2020120021110 · Cited by 8
Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS
Thompson, A. G., Gray, E., Charles, P. D., Hu, M. T. M., Talbot, K., Fischer, R., Kessler, B. M., & Turner, M. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.642324 · Cited by 7
Designing a Small Molecule for PET Radiotracing: [18F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies
Mastropasqua, F., Luurtsema, G., Filosa, C., & Colabufo, N. A. (2025) · Molecules · doi:10.3390/molecules30183696 · Cited by 6
Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice
Duong, Q.-V., Kintzing, M. L., Kintzing, W. E., Abdallah, I. M., Brannen, A. D., & Kaddoumi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061489 · Cited by 6
Implication de la barrière hématoencéphalique dans la physiopathologie des maladies neurologiques : Partie II
Weiss, N., Miller, F., Cazaubon, S. M., & Couraud, P. (2009) · Revue Neurologique · doi:10.1016/j.neurol.2009.04.013 · Cited by 6
Adult Neurogenesis, Neuroinflammation, and Therapeutic Potential of Adult Neural Stem Cells
Taupin, P. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195326697.003.0010 · Cited by 6
Neurodegeneration from Drugs and Aging‐Derived Free Radicals
Ramkissoon, A., Shapiro, A. M., Loniewska, M. M., & Wells, P. G. (2013) · Wiley eBooks · doi:10.1002/9781118355886.ch10 · Cited by 6
Aquaporin 4 beyond a water channel; participation in motor, sensory, cognitive and psychological performances, a comprehensive review
Jazaeri, S. Z., Taghizadeh, G., Fahanik‐Babaei, J., Goudarzi, S., Saadatmand, P., Joghataei, M. T., & Khanahmadi, Z. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114353 · Cited by 6
Protective effects of Tenebrio molitor and Protaetia brevitarsis seulensis extracts on aging: Regulation of blood–brain barrier, amyloid β plaques, and intestinal inflammation in D-galactose-induced aging mice
Trân, N. B., Lee, H., & Lee, S.-J. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106333 · Cited by 5
The Impact of Persistent Noise Exposure under Inflammatory Conditions
Cho, I., Kim, J., Jung, S., Kim, S. Y., Kim, E. J., Choo, S., Kam, E. H., & Koo, B. (2023) · Healthcare · doi:10.3390/healthcare11142067 · Cited by 5
Examining Stromal Cell Interactions in an In Vitro Blood–Brain Barrier Model with Human Umbilical Vein Endothelial Cells
Margari, A., Konig, S., Jayarajan, V., Rizzato, S., Maruccio, G., & Moeendarbary, E. (2025) · Cells · doi:10.3390/cells14110759 · Cited by 5
A role of P-glycoprotein in neurology
Chernykh, I. V., Shchulkin, A. V., Yakusheva, E. N., & Popova, N. M. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171171167-71 · Cited by 5
Oxidants and Endothelial Dysfunction
Lund, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65250-9 · Cited by 6
Common Pathways to Neurodegeneration and Co-morbid Depression
Litteljohn, D., Mangano, E. N., & Hayley, S. P. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_8 · Cited by 5
Intermittent fasting protects MPTP-induced Parkinson's disease mouse model through regulating gut microbiota dysbiosis
Qu, Y., Wang, P., Wang, D., Li, B., & Yang, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116447 · Cited by 4
The role of blood-brain barrier integrity in the pathophysiology and progression of psychiatric disorders
Konstantinou, G., & Warsh, J. J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106658 · Cited by 6
Critical Role of Neuronal Vps35 in Blood Vessel Branching and Maturation in Developing Mouse Brain
Zhao, Y., Lee, D., Zhu, X., & Xiong, W. (2022) · Biomedicines · doi:10.3390/biomedicines10071653 · Cited by 4
Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle?
Ferré‐González, L., Balaguer, Á., Roca, M., Ftara, A., Lloret, A., & Cháfer‐Pericás, C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01549-x · Cited by 4
Modulating Role of TTR in Aβ Toxicity, from Health to Disease
Cardoso, I., Santos, L. M., & Alemi, M. (2016) · InTech eBooks · doi:10.5772/63194 · Cited by 7
Transcriptome sequencing reveals circRNA expression profile in Parkinson's disease-like mice after aerobic exercise
FAN, T., LI, X., FU, C., & SUN, L. (2022) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2611 · Cited by 4
Polymeric Biomaterials for Medical Diagnostics in the Central Nervous System
Yin, Y., Rassias, D., & Jain, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396983-5.00023-5 · Cited by 4
Whole-exome analysis in Parkinson’s disease reveals a high burden of ultra rare variants in early onset casesPreprint
Bustos, B. I., Krainc, D., & Lubbe, S. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.06.137299 · Cited by 5
Claudin proteins and hemorrhage severity in aneurysmal subarachnoid hemorrhage: Correlation with modified Fisher score but not functional outcome
Lenzsér, G., Szebeni, G. J., Balogh, F., Gémes, N., Schwarcz, A., & Csécsei, P. (2025) · Neurosurgical Review · doi:10.1007/s10143-025-03829-y · Cited by 3
Insights into receptor tyrosine kinases signaling in neurodegenerative disorders
Randhawa, P. K., Jaggi, A. S., & Bali, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18677-6.00001-4 · Cited by 3
Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision
Niazi, S. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810211 · Cited by 3
High-fat diet-induced cellular neuroinflammation: Alteration of brain functions and associated aliments
Umare, M. D., Bajaj, K. K., Wankhede, N. L., Taksande, B. G., Upaganlawar, A., Umekar, M. J., & Kale, M. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89834-8.00031-3 · Cited by 3
The potential protective role of peripheral immunophenotypes in Alzheimer’s disease: a Mendelian randomization study
Zuo, C., Hu, Z., Fan, Y., Hao, X., Li, M.-J., Shi, J.-J., Guo, M.-N., Ma, D., Liang, Y., Liang, Y.-Y., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1403077 · Cited by 4
Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
Karim, S., Mirza, Z., Kamal, M. A., Abuzenadah, A. M., & Al-Qahtani, M. H. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023122803 · Cited by 3
Neurogenic factors are targets in depression
Taupin, P. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.09.002 · Cited by 3
Polymeric Nanomedicine
Zhao, Y., Zheng, C., & Liu, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-8731-9_9 · Cited by 3
Non‐contrast estimate of blood–brain barrier permeability in humans using arterial spin labeling and magnetization transfer at 7 T
Mahmud, S. Z., Denney, T. S., & Bashir, A. (2023) · NMR in Biomedicine · doi:10.1002/nbm.4908 · Cited by 3
Disease Influence on BBB Transport in Neurodegenerative Disorders
de Lange, E. C. M. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_22 · Cited by 3
Calcium Signaling at the Blood–Brain Barrier in Stroke
Brown, R. C. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9663-3_6 · Cited by 3
A single domain shark antibody targeting the transferrin receptor 1 delivers a TrkB agonist antibody across the blood brain barrier to provide full neuroprotection in a mouse model of Parkinson’s DiseasePreprint
Clarke, E., Sinclair, L., Fletcher, E. J. R., Krawczun-Rygmaczewska, A., Duty, S., Stocki, P., Rutkowski, J. L., Doherty, P., & Walsh, F. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.987313 · Cited by 3
Material considerations for delivering therapeutics across the blood–brain barrier
Zoba, A. N., & Tringides, C. M. (2025) · APL Materials · doi:10.1063/5.0284305 · Cited by 2
Intranasal vs. Device-Assisted Drug Delivery: Advantages and Limitations for the Delivery of Biopharmaceuticals to the CNS
Martini, L., Valori, C. F., Morrone, M., Brambilla, L., & Rossi, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040484 · Cited by 2
Therapeutic role of nutraceuticals in the management of brain disorders
Benmelouka, A. Y., Shah, M. A., Saleem, U., Elshanbary, A. A., Meshref, M. M., Shah, G. M., Alsharif, I., Althobaiti, N. A., & Alhasani, R. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824356-5.00012-6 · Cited by 2
Oxidants and Endothelial Dysfunction
Lund, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00071-1 · Cited by 2
Volumetric Analysis of the Blood–Brain Barrier After Ischemic Stroke by Electron Tomography in Mice
Kotchetkov, P., & Lacoste, B. (2025) · Microcirculation · doi:10.1111/micc.70025 · Cited by 2
Increasing interleukin-17 induced by β-Amyloid deposition is involved in early cognitive decline after sevoflurane anesthesia
Zhao, Q., Ma, Y., Zhang, X., Zhang, M., Wang, Z., Chen, X., Duan, F., Chen, D., & Yu, Z. (2025) · Experimental Brain Research · doi:10.1007/s00221-025-07194-6 · Cited by 2
Functional activity of p-glycoprotein in blood-brain barrier during experimental par-kinson's syndrome
Chernykh, I. V., Shchulkin, A. V., Mylnikov, P. Y., Gatsanoga, M. V., Gradinar, M. M., Есенина, А. С., & Yakusheva, E. N. (2019) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj2019272150-159 · Cited by 2
Induction of Transporter Protein Glycoprotein-P in the Blood–Brain Barrier as a Way to Prevent Parkinson’s Syndrome
Gradinar, M. M., Chernykh, I. V., Shchulkin, A. V., Есенина, А. С., & Yakusheva, E. N. (2020) · Neurochemical Journal · doi:10.1134/s1819712420030046 · Cited by 2
Neurodegenerative Diseases and the Gut Microbiota
Cabré, S., O’Riordan, K. J., & Cryan, J. F. (2022) · Progress in inflammation research · doi:10.1007/978-3-030-91051-8_11 · Cited by 2
Data-Driven Approaches Used for Compound Library Design for the Treatment of Parkinson’s Disease
Barrera-Vázquez, O. S., Santiago-de-la-Cruz, J. A., Rivero-Segura, N. A., Estrella-Parra, E. A., Morales-Paoli, G. S., Flores‐Soto, E., & Gómez-Verján, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021134 · Cited by 2
Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease
Contaldi, E., Magistrelli, L., & Comi, C. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00008-4 · Cited by 3
PLGA-based nanoparticles for treatment of cerebral diseases
Chacko, J. B., & Jose, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91215-0.00018-2 · Cited by 2
The effects of Korean Red Ginseng on heme oxygenase-1 with a focus on mitochondrial function in pathophysiologic conditions
Kim, C., Kim, H. Y., Nah, S.-Y., & Choi, Y. K. (2023) · Journal of Ginseng Research · doi:10.1016/j.jgr.2023.04.001 · Cited by 2
Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases
Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_8 · Cited by 2
Challenges in Neurorestoration: A Special Issue for the 14th Annual American Society for Neural Therapy and Repair (ASNTR) Meeting
Emborg, M. E. (2007) · Cell Transplantation · doi:10.3727/000000007783464722 · Cited by 2
A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculaturePreprint
Kemble, A. M., Hornsperger, B., Ruf, I., Richter, H. G., Benz, J., Kuhn, B., Heer, D., Wittwer, M., Engelhardt, B., Grether, U., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.04.490688 · Cited by 2
BBB-on-a-chip with Integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer’s diseasePreprint
Palma-Florez, S., López-Canosa, A., Morales-Zavala, F., Castaño, Ó., Kogan, M. J., Samitier, J., Lagunas, A., & Mir, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.05.505851 · Cited by 2
miR-142 regulates the function of microvascular endothelial cells through MAT2B
Liu, C.-Y., Chen, D.-C., Zhang, Z.-H., Li, T., & Ji, L.-L. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110501 · Cited by 2
Intelligent Biomaterials and Microfluidic Technology
Tan, C. S., He, M., Guo, Y., & Fu, J. (2025) · Springer eBooks · doi:10.1007/978-981-96-8646-9_10 · Cited by 1
Exploring self-nanoemulsifying drug delivery system (SNEDDS) in combating neurodegeneration: a revolutionary tool for drug targeting in Alzheimer’s and Parkinson’s disease
Tyagi, S., Kumar, J., & Kumar, S. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2580488 · Cited by 1
Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases
Kalita, R., Sarma, A., Baruah, H., Zaman, A., & Goswami, D. (2026) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.70021 · Cited by 3
Taurine modulates gut microbiota and attenuates inﬂammation in a rotenone-induced mouse model of Parkinson's disease
Zhu, Y., Wang, S., Zhao, S., Zeng, Y., Li, J., Wang, P., Dou, Z., & Wang, T. (2026) · NeuroToxicology · doi:10.1016/j.neuro.2026.103401 · Cited by 1
Is Chronic Systemic Inflammation a Determinant Factor in Developing Parkinson’s Disease?
Ugalde‐Muñiz, P., Pérez‐Hernández, J., & Chavarría, A. (2016) · InTech eBooks · doi:10.5772/62955 · Cited by 1
Intralipid treatment for Alzheimer Disease
Eldor, J. (2017) · Clinical and Medical Investigations · doi:10.15761/cmi.1000139 · Cited by 1
Cerebrospinal fluid proteomics reveals the innate immunity and blood-brain barrier dysregulation in a patient with multidrug-resistant Acinetobacter baumannii ventriculitis treated with intrathecal and intravenous polymyxin B
Li, M., Liu, D., Bergen, P. J., Liang, S., Chen, J., Kho, Z. Y., Lu, J., Sun, H., Hong, W., Liu, X., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40893 · Cited by 1
Beta-caryophyllene inhibits the permeability of the blood–brain barrier in MPTP-induced parkinsonism
Ramos-Molina, A. R., Tejeda-Martínez, A. R., Paredes, J. M. V., Chaparro-Huerta, V., Urmeneta-Ortíz, M. F., Ramírez-Jirano, L. J., & Flores-Soto, M. E. (2025) · Neurología (English Edition) · doi:10.1016/j.nrleng.2025.02.003 · Cited by 1
Effects of Lycium barbarum on Modulation of Blood Vessel and Hemodynamics
Mi, X.-S., Huang, R., Ding, Y., Chang, R. C., & So, K. (2015) · Springer eBooks · doi:10.1007/978-94-017-9658-3_4 · Cited by 1
Advanced radiological investigation of levodopa- induced dyskinesia in Parkinson’s disease patients: assessment of blood brain barrier function
Segal, O., Mardor, Y., Orbach, L., Hoffman, C., & Hassin‐Baer, S. (2022) · Neurology Asia · doi:10.54029/2022ycu · Cited by 1
Studies on pericytes in health and disease
Nisancioglu, M. H. (2010) · Figshare · Cited by 1
Graphene‐Based Materials for Brain Targeting
Aderibigbe, B. A., Naki, T., & Owonubi, S. J. (2019) · Wiley eBooks · doi:10.1002/9781119468455.ch120 · Cited by 1
A Non-invasive Detection of Parkinson’s Disease using PitArray: An Integrative Meta-Analysis and Machine Learning ApproachPreprint
Bhattacharjee, A., Jamal, T. B., Ahammad, I., Lamisa, A. B., Arefin, M. S., Chowdhury, Z. M., Hossain, M. U., Das, K. C., Keya, C. A., & Salimullah, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.15.562440 · Cited by 1

Authors: Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B.
Affiliations: Department of Pharmacology, Rush University Medical Center, Chicago IL, USA
Rush University Medical Center (US)
Venue: Cell Transplantation
Publisher: SAGE Publications
Published: 2007-03
Volume: 16
Issue: 3
Pages: 285-299
ISSN: 0963-6897 (ISSN-L)
1555-3892
DOI: 10.3727/000000007783464731
OpenAlex: W2316522881
Cited by: 339
References: 117
Citations by year: 2026: 13 · 2025: 14 · 2024: 28 · 2023: 31 · 2022: 23 · 2021: 33 · 2020: 37 · 2019: 13 · 2018: 15 · 2017: 16 · 2016: 11 · 2015: 12 · 2014: 12 · 2013: 18 · 2012: 8
FWCI: 1.29
Type: journal article
Language: en
Open access: green
doaj.org
Licence: cc-by-sa
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Cell Transplantation (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health (5r01ns045316-03, W81XWH-04-01-0365)
U.S. Public Health Service (012307)
National Institute of Allergy and Infectious Diseases (R01AI051619, R01AI51619)
National Institute of Neurological Disorders and Stroke (NS045316)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: blood-brain barrier, Alzheimer's disease, Parkinson's disease, BBB dysfunction, tight junctions, blood-brain barrier permeability, neuroinflammation, neurodegeneration, brain drug delivery, vessel density, neurodegenerative disease therapeutics
MeSH terms: Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Humans, Parkinson Disease, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks